6533b826fe1ef96bd1283ccb
RESEARCH PRODUCT
Interleukin-22 in Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation
Baptiste ElamartheeBaptiste ElamartheeFlorent EmalardFlorent EmalardPhilippe EsaasPhilippe EsaasPhilippe EsaasMohamad EmohtyMohamad EmohtyMohamad EmohtyBeatrice EgauglerBeatrice Egauglersubject
0301 basic medicinelcsh:Immunologic diseases. Allergy[SDV.IMM] Life Sciences [q-bio]/Immunologyalloreactivitymedicine.medical_treatmentImmunologyInflammationchemical and pharmacologic phenomenaHematopoietic stem cell transplantationReviewBiologyInterleukin 2203 medical and health sciencesgraft-versus-host-disease0302 clinical medicineImmune systemimmune system diseasesallogeneic stem cell transplantationmedicinegraft-versus-host diseaseImmunology and AllergyInflammationInnate immune systeminterleukin-22medicine.disease3. Good healthTransplantation030104 developmental biologyGraft-versus-host diseasesurgical procedures operativeImmunology[SDV.IMM]Life Sciences [q-bio]/Immunologymedicine.symptomStem celllcsh:RC581-607030215 immunologydescription
International audience; Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potential curative treatment for hematologic malignancies and non-malignant diseases. Because of the lower toxicity of reduced intensity conditioning, the number of transplants is in constant increase. However, allo-HSCT is still limited by complications, such as graft-versus-host disease (GVHD), which is associated with important morbidity and mortality. Acute GVHD is an exacerbated inflammatory response that leads to the destruction of healthy host tissues by donor immune cells. Recently, the contribution of innate immunity in GVHD triggering has been investigated by several groups and resulted in the identification of new cellular and molecular effectors involved in GVHD pathogenesis. Interleukin-22 (IL-22) is produced by both immune and adaptive cells and has both protective and inflammatory properties. Its role in GVHD processes has been investigated, and the data suggest that its effect depends on the timing, the target tissue, and the origin of the producing cells (donor/host). In this review, we discuss the role of IL-22 in allo-HSCT and GVHD.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2016-04-19 |